抑郁症筛查后患者靶向反馈的临床有效性:GET.FEEDBACK.GP随机对照试验
GET.FEEDBACK.GP是在德国64家全科诊所开展的多中心三臂观察者盲随机对照试验,纳入PHQ-9≥10且尚未确诊的抑郁筛查阳性患者,比较无反馈、仅全科医生反馈、全科医生加患者反馈三种策略。6个月时三组PHQ-9评分均改善,但组间无显著差异,患者靶向反馈未带来额外获益,也未观察到自杀倾向增加。
要点
- 三组6个月PHQ-9均改善,组间差异无统计学意义(整体p=0·13)
- 全科医生加患者反馈组对比无反馈组PHQ-9差异为-0·77(95%CI -1·60至0·07,d=-0·16)
- 未观察到自杀倾向作为不良事件增加
核心结论
- 抑郁症筛查后向患者和全科医生提供靶向反馈,与仅全科医生反馈或无反馈相比,未显著降低抑郁严重程度。
研究设计与样本
- 研究者发起的多中心三臂观察者盲随机对照试验,在德国5个地区64家全科诊所开展。
- 等候就诊的≥18岁、PHQ-9≥10、德语熟练且尚未确诊抑郁的患者按1:1:1随机分组,按治疗全科医生和PHQ-9严重程度分层。
- 主要结局为随机化后6个月PHQ-9测量的抑郁严重程度,对至少有一次随访的患者行意向性治疗分析。
主要发现
- 25 279名患者接受资格筛查,8129人完成筛查,其中1030人(12·7%)筛查阳性。
- 344人分入无反馈组、344人分入全科医生反馈组、339人分入全科医生加患者反馈组。
- 6个月主要结局分析纳入无反馈组252人(73%)、全科医生反馈组252人(73%)、全科医生加患者反馈组256人(76%),随访率74%。
- 基线至6个月PHQ-9评分变化:无反馈组-4·15(95%CI -4·99至-3·30),全科医生反馈组-4·19(-5·04至-3·33),全科医生加患者反馈组-4·91(-5·76至-4·07),三组间无显著差异(整体p=0·13)。
- 全科医生加患者反馈组与仅全科医生反馈组比较,PHQ-9差异为-0·73(95%CI -1·56至0·11,d=-0·15);未观察到任一组自杀倾向作为不良事件增加。
临床怎么用
- 结果提示仅靠筛查后向患者和全科医生提供书面靶向反馈,不足以在整体上额外减轻抑郁严重程度。
- 对筛查阳性者仍需结合常规诊疗路径评估与随访,不宜将单次反馈视为改善结局的充分干预。
局限性
- 研究在德国全科诊所开展,结论外推至其他医疗体系需谨慎。
- 主要结局分析仅纳入有随访的患者,随访率为74%。
- 作者指出需进一步研究筛查结合系统反馈对特定亚组的潜在特异性效果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Screening for depression in primary care alone is not sufficient to improve clinical outcomes. However, targeted feedback of the screening results to patients might result in beneficial effects. The GET.FEEDBACK.GP trial investigated whether targeted feedback of the depression screening result to patients, in addition to feedback to general practitioners (GPs), leads to greater reductions in depression severity than GP feedback alone or no feedback. METHODS: The GET.FEEDBACK.GP trial was an investigator-initiated, multicentre, three-arm, observer-blinded, randomised controlled trial. Depression screening was conducted electronically using the Patient Health Questionnaire-9 (PHQ-9) in 64 GP practices across five regions in Germany while patients were waiting to see their GP. Currently undiagnosed patients (aged ≥18 years) who screened positive for depression (PHQ-9 score ≥10), were proficient in the German language, and had a personal consultation with a GP were randomly assigned (1:1:1) into a group that received no feedback on their depression screening result, a group in which only the GP received feedback, or a group in which both GP and patient received feedback. Randomisation was stratified by treating GP and PHQ-9 depression severity. Trial staff were masked to patient enrolment and study group allocation and GPs were masked to the feedback recieved by the patient. Written feedback, including the screening result and information on depression, was provided to the relevant groups before the consultation. The primary outcome was PHQ-9-measured depression severity at 6 months after randomisation. An intention-to-treat analysis was conducted for patients who had at least one follow-up visit. This study is registered at ClinicalTrials.gov (NCT03988985) and is complete. FINDINGS: Between July 17, 2019, and Jan 31, 2022, 25 279 patients were approached for eligibility screening, 17 150 were excluded, and 8129 patients completed screening, of whom 1030 (12·7%) screened positive for depression. 344 patients were randomly assigned to receive no feedback, 344 were assigned to receive GP-targeted feedback, and 339 were assigned to receive GP-targeted plus patient-targeted feedback. 252 (73%) patients in the no feedback group, 252 (73%) in the GP-targeted feedback group, and 256 (76%) in the GP-targeted and patient-targeted feedback group were included in the analysis of the primary outcome at 6 months, which reflected a follow-up rate of 74%. Gender was reported as female by 637 (62·1%) of 1025 participants, male by 384 (37·5%), and diverse by four (0·4%). 169 (16%) of 1026 patients with available migration data had a migration background. Mean age was 39·5 years (SD 15·2). PHQ-9 scores improved for each group between baseline and 6 months by -4·15 (95% CI -4·99 to -3·30) in the no feedback group, -4·19 (-5·04 to -3·33) in the GP feedback group, and -4·91 (-5·76 to -4·07) in the GP plus patient feedback group, with no significant difference between the three groups (global p=0·13). The difference in PHQ-9 scores when comparing the GP plus patient feedback group with the no feedback group was -0·77 (-1·60 to 0·07, d=-0·16) and when comparing with the GP-only feedback group was -0·73 (-1·56 to 0·11, d=-0·15). No increase in suicidality was observed as an adverse event in either group. INTERPRETATION: Providing targeted feedback to patients and GPs after depression screening does not significantly reduce depression severity compared with GP feedback alone or no feedback. Further research is required to investigate the potential specific effectiveness of depression screening with systematic feedback for selected subgroups. FUNDING: German Innovation Fund. TRANSLATION: For the German translation of the abstract see Supplementary Materials section.
引用
- Löwe B, Scherer M, Braunschneider LE, et al. Clinical effectiveness of patient-targeted feedback following depression screening in general practice (GET.FEEDBACK.GP): an investigator-initiated, prospective, multicentre, three-arm, observer-blinded, randomised controlled trial in Germany. Lancet Psychiatry. 2024. PMID: 38432236. doi:10.1016/S2215-0366(24)00035-X
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。